Abstract Cancer is a disease characterized by genomic instability and aberrant DNA repair. Poly (ADP-ribose) polymerase-1 (PARP-1) represents a well-established therapeutic target, particularly in ovarian and prostate cancer. However, the currently approved PARP inhibitors face challenges such as resistance, toxicity, and reduced efficacy. The search for alternative scaffolds has therefore become increasingly urgent. In this study, we used an integrated approach combining computer-aided methods
Computational discovery of emodin-based anthraquinones as PARP-1 inhibitors with relevance to ovarian and prostate cancer
Sohag Ahmed·Vetriselvan Subramaniyan·Abdullah Al Noman·Md Mohi Uddin·Ahmed Nasim·Monotosh Kumar Sarkar·Shu Shanta·Rubel Hossain·Subrato Das·Chinmoy Saha·Md Shafiqul Islam Sovon·Fahmida Akter·Chetan Ashok·Srikanth Jeyabalan·Thakur Gurjeet Singh·Ling Shing Wong·Subash Chandra Shaha·Abdulla All Maruf
